Testing Dexmedetomidine with General Anesthesia in Children Aged 3 to 12 Undergoing Catheter Closure of Atrial Septal Defect

What this Trial Is About

This trial investigates the use of dexmedetomidine to improve recovery quality and maintain stable heart function in children aged 3 to 12 undergoing interventional catheter closure of atrial septal defect ASD. Researchers also aim to understand whether dexmedetomidine reduces stress responses and affects recovery timing like time to extubation and emergence delirium in this pediatric group. Participants receive either dexmedetomidine or a placebo alongside general anesthesia with sevoflurane. Dexmedetomidine is given as a loading dose of 1 microgram per kilogram over 10 minutes, followed by an infusion of 0.5 microgram per kilogram per hour via a syringe pump. The placebo group receives a matching saline infusion prepared by an independent party. Hemodynamic parameters are monitored before, during, and after the procedure. Throughout the study, heart rate, blood pressure, and cardiac output are measured at baseline and perioperatively. Researchers also assess recovery quality, recovery time, time to extubation, stress hormone levels, and any side effects. The trial includes close monitoring of emergence delirium and stress hormone sampling before and after the procedure, with the goal of understanding dexmedetomidines effects on pediatric recovery and stress during ASD closure.

Effect of Dexmedetomidine Supplementation to General Anaesthesia in Paediatric Transcatheter Closure of Atrial Septal Defect